{"paper_id":"11035f18-5db6-4742-81e9-8c7f9887b824","body_text":"Sections 1 and 2 state purpose and scope, and section 3 defines responsibilities of the collection operator, the laboratory staff, and the project/program manager/director. Sections 4 and 5 contain references, definitions and abbreviations relevant to endometrial tissue and peripheral blood specimen collection, handling, processing, storage, and distribution. Section 6 includes a comprehensive list of materials, reagents and paperwork, complete and detailed formulation and procedural notes for reagent preparation, material/reagent vendors, and description of required materials and paperwork. These sections ensure proper and full implementation of the SOP.\n\nIn section 7, sample collection approvals address regulatory compliance with institutional biological safety guidelines and federally mandated internal IRB research protocols involving human subjects, including requirement for authorization from the institutional Biological Safety Committee, ensuring safeguard of personal and environmental safety in collection of human blood and tissues, and approval from the internal IRB, the UCSF Committee on Human Research, such that all activities under this SOP fully comply with applicable ethical standards, as well as patient safety and privacy protection. Also described are the procedural steps in obtaining informed consent from participating subjects, in compliance with local institutional, state, and federal regulations.\n\nSections 8–10 provide protocols for collection of blood and tissue specimens, with details of specimen handling, including sampling and processing, labeling, and required annotation of sample and subject information. Strict specimen segregation throughout processing and separate sets of sterile instruments are required, thus preventing potential acquisition of environmental contaminants or sample cross-contamination. Optimization of tissue collection and processing workflow ensures the quality of tissue preservation for molecular applications, and living cells and preserved intact tissue. The latter two samples are of particular importance for studies involving tissue localization, and functional/phenotype characterization using living cells. For molecular applications, particular attention is paid to the time between the excision of the tissue and its preservation (by snap freezing or submersion in RNA later ®), or warm ischemia time. Tissue ischemia time is critical in biospecimen processing for gene expression analysis, essential for reliable data in screening for molecular targets/diagnostic patterns, and important for data consistency in multicenter programs ( 6 ). The effects of tissue ischemia on gene expression microarray analysis have been documented for a variety of human tissues ( 6 – 12 ), and there is broad consensus on the importance of standardizing tissue procurement procedures and minimizing processing time ( 13 ). Our approach to tissue procurement is consistent with current consensus in the field, and under the current SOP, endometrial tissue samples allocated for RNA isolation are processed in the operating room and preserved typically within 10 minutes after excision. Validation of the procedure involved pre-chip and post-chip hybridization quality control (QC) measurements ( 14 ) on RNA isolated from 96 endometrial tissue specimens. Agilent Bioanalyzer RNA integrity number (RIN) data showed 92% of high-quality RNA samples (RIN scores >7) ( Figure 1 ) suitable for microarray analysis ( 15 ) and substantially higher than reported for biobanking of human pancreatic cancer tissue (42%) ( 16 ). Microarray data from 85 samples were subjected to standard QC measures of individual and group array quality examining distribution of perfect-match (PM) and background signal intensity, and intensities of probes targeting spiked-in transcripts and control genes. All arrays showed comparable shape and range of PM signal intensity distributions, and good separation between PM signal and background and between positive and negative control mRNA probes. Means of across-array comparison including percent present probes, average background signal, MAS5 scaling factor, and 3′/5′ probe ratios for GAPDH and ACTIN showed few outliers in the percent of probes present and/or 3′/5′ ratios of GAPDH and ACTIN probes, none of which were severe outliers for PM signal intensity or within-group correlation. All arrays had comparable average background and scaling factors, and none of the arrays needed to be excluded for technical reasons. Thus, the high RNA and array quality obtained with the SOP procurement protocol ensures the reliability and scientific usefulness of the data derived thereof.\nThe SOP workflow addresses parallel processing of tissue samples from individual specimens for three distinct applications (tissue sectioning/histology, RNA extraction, and cell isolation and culture), each having different handling requirements, and establishes an order of priority for processing samples for the different applications, in keeping with known requirements and recommendations ( 17 ), as follows: 1) RNA isolation (flash frozen, or immersed in RNA later ®); 2) histology/immunohistochemistry (fixed in 10% formalin and/or 4% paraformaldehyde); 3) frozen sectioning (OCT-embedded frozen ); 4) viable cell isolation (immersed in tissue transport medium). The order of priority reflects the critical importance of processing time in samples for RNA isolation compared to other applications. It is also important to ensure availability of adequate samples for histological evaluation of each endometrial specimen ( 18 ) since the endometrium undergoes major molecular and cellular cycle-dependent changes, and lack of reliable cycle phase determination for would compromise the accurate interpretation of molecular analyses.\n\nInstructions in sections 8–11 for labeling, lab processing, and final storage of samples ensure consistent, accurate, and unambiguous identification of all specimens and their derivatives, enabling efficient sample tracking and inventory.\n\nSince its inception, the NIH UCSF Human Endometrial Tissue and DNA Bank has accrued over 700 endometrial tissue and 150 blood samples, under approved IRB protocols, from women undergoing endometrial biopsy or benign gynecologic surgery, and is a national resource as a repository for human endometrial tissue, DNA, and blood specimens for NIH investigators and collaborators. The implementation of rigorous biobanking specimen protocols becomes essential to assure high quality specimens, sample consistency, accurate histologic characterization. Complete clinical annotation, and the development and implementation of this SOP for collecting, receiving, processing, storing, and handling samples are pivotal for high biospecimen quality essential for state of the art molecular applications. Functional genomics approaches applying microarray technologies to studying human endometrium ( 19 ) have led to discoveries of cycle phase-specific gene expression profiles ( 20 – 22 ) and previously unsuspected differences in gene expression in eutopic endometrium of women with endometriosis ( 23 ,  24 ). This underscores the importance of meticulous subject annotation, specimen procurement and phenotypic characterization for studies with human endometrium and exemplifies how control of biospecimen processing variables is essential to obtain reliable data in discovery of molecular targets and diagnostic molecular patterns. The current SOP addresses these critical issues - providing a synthesis of sound scientifically validated procedures, thorough documentation, and strict regulatory compliance relevant to the collection of endometrial samples in multiple clinical settings. The comprehensive and systematic approach to the procurement of human endometrial tissue and blood contained in this SOP, ensures the high degree of quality, reliability, and scientific usefulness of biospecimens procured and made available to investigators by the NIH UCSF Human Endometrial Tissue and DNA Bank. In addition, the detail and perspective in this SOP may provide a starting blueprint for implementing endometrial sample collection programs at other sites and institutions.","source_license":"CC0","license_restricted":false}